In HR (-) tumors, no significant survival difference of OS (88% vs. 87%, p=0.96, Figure 3(c)) and RFS (87% vs. 86%, p = 0.92, Figure 3(d)) could be observed in HER2-low-positive BC and HER2-0 BC. Here, ERBB2 is linked to breast cancer.